Navigation Links
Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says
Date:9/15/2009

ROCKVILLE, Md., Sept. 15 /PRNewswire-USNewswire/ -- Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality.

Drugs to reduce the risk of breast cancer can be prescribed to women with a family history of breast cancer or other risk factors, but prescribing practices vary widely. The comparative effectiveness review found that all three drugs -- tamoxifen, raloxifene, and tibolone -- significantly reduce invasive breast cancer in midlife and older women but that benefits and adverse effects can vary depending on the drug and the patient.

"Taking medicine to avoid breast cancer in the first place is an attractive notion, but the decision to do so must be made by patients in consultation with their clinicians with benefit of the best evidence available," said AHRQ Director Carolyn M. Clancy, M.D. "These drugs are not necessarily for everyone. This report sheds important light on their advantages and potential harms."

The report is the first to make a direct, comprehensive comparison of the drugs so that women and their health care providers can assess the medications' potential effectiveness and adverse effects. The report compares the use of the three drugs to reduce the risks of getting breast cancer in women who have not previously had breast cancer.

Breast cancer is the second most commonly diagnosed cancer of women (after skin cancer), with more than 190,000 new cases diagnosed each year in the United States. It is estimated to cause more than 40,000 deaths per year. The National Cancer Institute estimates that nearly 15 percent of women born today will develop breast cancer in their lifetimes. Most cases of breast cancer occur in women with no specific risk factors other than age and gender, alth
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
2. New Studies Show Popular Heartburn Medications Moderate the Effect of Taking Widely Prescribed Heart Drug
3. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
4. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
5. AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panels Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
6. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
7. Wedgewood Introduces Refresh(TM) Exchange-Program: Free Exchange of Expired Veterinary Compounded Medications Solves Key Industry Problem
8. Researchers Find High-Dose Therapy for Liver Disease Not Effective
9. Clinical Study Proves Pollogens TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch Marks
10. New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors
11. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) ... secured $1 million in 12% per annum short term ... is an initial drawdown of $500,000, with accrued interest ... of $500,000 with accrued interest and principal repayable in ... Company becoming cashflow positive for any calendar month prior ...
(Date:12/16/2009)... December 16 Scientists at,deCODE genetics, Inc. ... the,discovery of a version of a common single-letter ... with a major impact on susceptibility to type ... is not only large, but unusual:,if an individual ... risk of,T2D by more than 30% compared to ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 1Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 2Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 3Award recognizes 30 years of anti smoking work 59213 1Award recognizes 30 years of anti smoking work 59213 2Developing enzymes to clean up pollution by explosives 10312 1
... Results presented at the Movement Disorder Society's 11th,International ... 08, 2007 /PRNewswire-FirstCall/ -- New,information on the use ... disease (PD) was reported this week at The,Movement ... approved by the FDA May 17, 2006, for ...
... 8, 2007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today ... including efficacy, safety and improvements in,patient-centered ... (DPN) pain treated with the investigational ... and sigma-1 agonist. The data were ...
Other Medicine Technology:International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 2International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 3International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 4International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 5International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7
(Date:12/17/2009)... Children’s Hospital from nearby hot tub company helps raise money ... ... Salt Lake City, UT (PRWEB) December ... the donation of a Bullfrog Spa to aid in fund ... City, Utah. Primary Children’s Medical Center, serving child patients from ...
(Date:12/16/2009)... sector revenue increased by 5.7 percent in 2008 ... 2007, according to new data from the U.S. ... North American Industry Classification System as NAICS 62. ... come from the 2008 Service Annual Survey: ... of tables which provides estimates of revenue, sources ...
(Date:12/16/2009)... 16 Smart Balance, Inc. (Nasdaq: SMBL ... authorized a two-year stock repurchase program of up to ... program demonstrates the confidence we have in the prospects ... long-term value for all of our shareholders, while at ... Stephen Hughes, Smart Balance, Inc. Chairman and Chief Executive ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... gain full benefit from breakthroughs, experts say, , , WEDNESDAY, ... lines currently used for research come mostly from white ... mean that non-whites will benefit less from any medical ... experts say. , Blacks could be especially affected. In ... lines studied showed any traces of recent African ancestry, ...
Breaking Medicine News(10 mins):Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2
... of Texas, 181,legislators are being honored with the ... accomplishments on behalf of health care,during the 80th ... created the award in 1997 to honor state ... on issues important,to hospitals and health systems. ...
... WASHINGTON, Oct. 15 Arthur H. Rubenstein,MBBCh, executive vice ... medicine, and Robert G. Dunlop professor of medicine at ... board of directors of the,Association of Academic Health Centers., ... School of Medicine in New,York before assuming his current ...
... pose big stomach risks, study notes , , MONDAY, ... don,t tell their doctors that they take common over-the-counter ... omission, a new study has found. , "With nearly ... it is no wonder that adverse events are increasing ...
... PA and VANCOUVER, BC, Oct. 15 /PRNewswire/ - ... pain drugs, announced today it has successfully reached ... (FDA) under the,Special Protocol Assessment (SPA) process for ... (OROS(R) Hydromorphone) for the treatment of,chronic pain. A ...
... Calif., Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ... advanced cardiovascular disease, plans to announce its operating,results for ... closes on,Monday, October 22, 2007 and will host a ... its results. To participate in the conference call, ...
... by gift from P&G, PHILADELPHIA, Oct. 15 ... for Clinical Research & Education,today announced a commitment ... gift to the ACG Institute,s Capital Campaign boosts ... in more than $16 million to,support clinical research, ...
Other Medicine News:Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Association of Academic Health Centers Names University of Pennsylvania's Dr. Arthur H. Rubenstein Chairman of the Board of Directors 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2Health News:ACG Announces Generous Gift by Procter & Gamble 2
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: